Actively Recruiting

Age: 18Years - 70Years
All Genders
NCT07376603

IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features

Led by Qiaojuan Guo · Updated on 2026-01-29

169

Participants Needed

1

Research Sites

259 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This observational study aims to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone in patients with stage IB nasopharyngeal carcinoma (NPC) without high-risk features. The primary objective is to determine the therapeutic effectiveness of this approach

CONDITIONS

Official Title

IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histopathologically confirmed, newly diagnosed nasopharyngeal carcinoma
  • Age 18-70 years
  • Stage IB disease (T1-2N1M0) per the 9th edition AJCC/UICC staging system
  • Upper-neck nodal metastasis only with inferior border of every positive node at or above the inferior border of the hyoid bone
  • ECOG performance status 0-2
  • Adequate bone-marrow function
Not Eligible

You will not qualify if you...

  • Age above 70 years or below 18 years
  • Matted lymph nodes: two or more contiguous nodes forming a confluent mass
  • Largest metastatic lymph-node 3 cm or larger in longest dimension
  • Lower-neck nodal metastasis with any positive node below the inferior border of the hyoid bone
  • Prior malignancy except adequately treated basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix
  • Pregnancy or lactation (serum pregnancy test required for women of child-bearing potential; effective contraception mandatory during treatment)
  • Previous radiotherapy to the head-and-neck region
  • Prior chemotherapy or surgery for the primary tumour or metastatic nodes (diagnostic procedures excluded)
  • Any severe comorbidity that would increase risk or affect protocol adherence, such as unstable cardiac disease, renal failure, chronic hepatitis, or uncontrolled psychiatric disorder
  • History of severe hypersensitivity reactions

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fujian Cancer Hospital

Fuzhou, Fujian, China, 350000

Actively Recruiting

Loading map...

Research Team

Q

Qiaojuan Guo, Professor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here